Chondroradionecrosis is a delayed complication of head and neck or thoracic radiotherapy in which irradiated cartilage and adjacent bone undergo progressive necrosis. It is treated as part of UHMS recognised condition #11 (Delayed Radiation Injury, sub-category radiation damage affecting bone) on Health Canada's 14 recognised conditions list, and hyperbaric oxygen therapy is publicly funded at all 11 Canadian hospital hyperbaric programmes with a physician referral. Laryngeal chondroradionecrosis after head-and-neck radiotherapy is the most-common single presentation in Canadian practice.
Quick Answer
Does HBOT help chondroradionecrosis? Chondroradionecrosis is a delayed complication of head and neck or thoracic radiotherapy in which irradiated cartilage and adjacent bone undergo progressive necrosis. It is treated as part of UHMS recognised condition #11 (Delayed Radiation Injury, sub-category radiation damage affecting bone) on Health Canada's 14 recognised conditions list, and hyperbaric oxygen therapy is publicly funded at all 11 Canadian hospital hyperbaric programmes with a physician referral. Laryngeal chondroradionecrosis after head-and-neck radiotherapy is the most-common single presentation in Canadian practice.
Chondroradionecrosis is a delayed complication of radiotherapy in which previously irradiated cartilage and adjacent bone undergo progressive necrosis months to years after treatment. The condition is also called radio-chondronecrosis or laryngeal radionecrosis when it affects the larynx (the most-common single presentation), or costal chondronecrosis when it affects the costal cartilage of the chest wall. It is uncommon in absolute numbers (estimated 1 to 5 percent of patients receiving curative-intent head-and-neck radiotherapy develop laryngeal chondroradionecrosis over the years following treatment) but carries significant morbidity when it does occur, with potential for airway compromise, debilitating pain, and the need for major reconstructive surgery.
**Laryngeal chondroradionecrosis** is the most common Canadian presentation, almost always developing in patients treated for laryngeal or hypopharyngeal cancer with curative-intent external-beam radiotherapy (typically 65 to 70 Gy in 30 to 35 fractions). It is a clinically distinct entity from the much more common mandibular osteoradionecrosis (ORN) and often misdiagnosed as the latter or as cancer recurrence. Symptoms include persistent throat pain, dysphagia, hoarseness, weight loss, and (in severe cases) airway compromise from cartilage collapse and airway narrowing. The standard radiologic and endoscopic findings include cartilage fragmentation, perichondral inflammation, and (in advanced cases) frank cartilage exposure or sequestrum formation. Distinguishing chondroradionecrosis from local cancer recurrence is one of the most challenging diagnostic problems in post-radiation head-and-neck care and typically requires biopsy with multidisciplinary tumour-board review. Untreated, severe laryngeal chondroradionecrosis can require total laryngectomy as a salvage procedure.
**Costal chondronecrosis** is less common and typically follows thoracic radiotherapy for breast cancer, lung cancer, or thoracic-wall malignancy. Clinical presentation includes localised chest-wall pain, palpable bony or cartilaginous irregularity, and (rarely) draining sinus or pathological fracture. Other irradiated cartilaginous structures (cricoid, tracheal rings, costoclavicular cartilage) can occasionally be affected, with the same general pattern of progressive ischaemic necrosis.
Approximately 8,200 Canadians are estimated to be diagnosed with head and neck cancers in 2026 (Canadian Cancer Society), and a substantial proportion receive curative-intent radiotherapy. The patient population at risk for laryngeal chondroradionecrosis is therefore meaningful, even though the absolute number of HBOT referrals for this specific indication remains modest.
Hyperbaric oxygen therapy treats chondroradionecrosis through the standard model for late radiation tissue injury, with specific application to cartilage and bone. The pathophysiology overlaps substantially with osteoradionecrosis, but the response of cartilage to HBOT differs in important ways from the response of bone, and these differences are clinically relevant.
The central pathological problem is the same: radiation-induced obliterative endarteritis of the small vessels that supply the irradiated cartilage and adjacent bone, producing progressive tissue hypoxia, fibrosis, and ultimately necrosis over months to years. Inside the chamber at 2.0 to 2.4 ATA on 100 percent oxygen, plasma oxygen content rises 10- to 15-fold, raising tissue pO2 in the irradiated cartilage and adjacent bone to several hundred mmHg during each session. Repeated intermittent hyperoxia stimulates VEGF release and angiogenesis, raising capillary density in the perichondrium and adjacent bone over 30 to 60 sessions.
A critical anatomical and biological difference between cartilage and bone responses to HBOT: cartilage is largely avascular, with chondrocytes deriving their oxygen and nutrients by diffusion from the perichondrium and adjacent vascular tissue. Cartilage cannot directly revascularise the way bone can. HBOT therefore works on cartilage primarily by improving the perichondrial blood supply and the oxygenation of the surrounding bony and soft-tissue envelope, rather than by direct neovascularisation of the cartilage matrix itself. This means that response to HBOT in chondroradionecrosis is generally slower than in pure osteoradionecrosis, that long-standing severe cartilage destruction has limited recoverability, and that surgical reconstruction (with HBOT support before and after) is more often required for definitive management than in the typical mandibular ORN case.
In parallel, HBOT supports osteoclast and osteoblast activity in the adjacent bone, restores oxygen-dependent neutrophil bactericidal activity (relevant when secondary infection is present), and reduces chronic inflammatory cascade activity in the irradiated tissue.
Typical Treatment Protocol
Standard course is 2.0 to 2.4 ATA on 100 percent oxygen for 90 minutes per session, delivered five days per week. Total course depends on the clinical scenario. For established chondroradionecrosis without planned surgical resection, 30 to 40 sessions is typical, with extension to 60 sessions in cases that show partial response and continued improvement at the standard endpoint. Treatment-response evaluation typically occurs at sessions 20, 30, and the end of the course, with serial imaging and endoscopy where appropriate. For cases requiring surgical resection or reconstruction, the Marx-style 30-and-10 protocol (extended from mandibular ORN to chondroradionecrosis) is the most common approach: 30 HBOT sessions before the planned surgery and 10 sessions afterward. This regimen optimises the tissue oxygenation environment for the planned surgery, improves probability of graft or flap take, and supports post-operative healing. For laryngeal chondroradionecrosis with airway compromise, ENT-led airway stabilisation comes first; HBOT is initiated after the airway is secured, in coordination with the treating otolaryngology team.
Level B - Moderate Evidence
Supported by controlled studies and clinical evidence
Chondroradionecrosis is recognised as a sub-presentation of UHMS condition #11 (Delayed Radiation Injury) under the radiation-damage-affecting-bone sub-category. It is publicly funded at all 11 Canadian hospital hyperbaric programmes under OHIP, MSP, AHCIP, RAMQ, MSI, MCP, and Saskatchewan Health.
Laryngeal chondroradionecrosis is the most-common single presentation in Canadian practice, almost always developing in patients treated for laryngeal or hypopharyngeal cancer with curative-intent external-beam radiotherapy (typically 65 to 70 Gy in 30 to 35 fractions). It is clinically distinct from the much more common mandibular osteoradionecrosis and is often misdiagnosed.
Cartilage response to HBOT differs from bone response: cartilage is largely avascular and cannot directly revascularise. HBOT works on cartilage primarily by improving the perichondrial blood supply and the oxygenation of the surrounding bony and soft-tissue envelope. Response is generally slower than in pure osteoradionecrosis, and surgical reconstruction is more often required for definitive management.
The Bennett 2016 Cochrane Review (PMID 27123955) of HBOT for late radiation tissue injury supports HBOT for radiation damage affecting bone, including the cartilage-and-bone necrosis seen in chondroradionecrosis. Specific RCT evidence for chondroradionecrosis alone is limited because of its low incidence; most evidence comes from case-series and observational data plus the broader radiation-injury literature.
Standard treatment course is 30 to 40 daily sessions at 2.0 to 2.4 ATA on 100 percent oxygen for 90 minutes per session, with extension to 60 sessions for severe or surgical cases. Marx-style 30-and-10 protocol applies when surgical resection or reconstruction is planned.
Distinguishing chondroradionecrosis from local cancer recurrence is one of the most challenging diagnostic problems in post-radiation head-and-neck care and typically requires biopsy with multidisciplinary tumour-board review.
Untreated severe laryngeal chondroradionecrosis can require total laryngectomy as a salvage procedure. Earlier referral after symptom onset, before extensive cartilage destruction develops, is associated with better outcomes.
Highest-evidence-tier studies tagged to this condition in the Canada Hyperbarics research database, ranked by evidence tier (1 = meta-analysis or RCT, 2 = cohort, 3 = case series), most recent first.
Respirol Case Rep · 2026 · Study
Head Neck · 2025 · Review
Diving Hyperb Med · 2024 · Case Report
Laryngoscope · 2015 · Case Report
Indian J Surg Oncol · 2014 · Review
Most patients with suspected chondroradionecrosis are referred to a hospital hyperbaric programme by their otolaryngologist, head-and-neck surgical oncologist, radiation oncologist, or thoracic surgeon after the diagnosis is confirmed. Pre-treatment work-up includes biopsy with multidisciplinary tumour-board review (to exclude cancer recurrence), imaging (CT or MRI of the affected region), and endoscopy where appropriate (laryngeal cases). The hyperbaric medicine team confirms eligibility, reviews imaging and biopsy findings, screens for absolute and relative contraindications, and books the treatment course.
Daily sessions begin within two to six weeks of consultation. You change into cotton scrubs (no synthetic fabrics, no skin lotions, no jewellery), enter the chamber, and lie down (in a monoplace) or sit in a recliner (in a multiplace with multiple patients). Pressurisation takes five to ten minutes and feels like the descent in an aircraft. The 90-minute treatment phase is on 100 percent oxygen at 2.0 to 2.4 ATA. Decompression takes another five to ten minutes. Total time on-site is typically two to three hours per visit.
Response is tracked clinically (pain, dysphagia, voice, weight, breathing) and by serial imaging and endoscopy. The hyperbaric medicine team coordinates closely with otolaryngology, head-and-neck surgery, radiation oncology, and (for surgical cases) plastic surgery throughout the course. Cartilage recovery is generally slower than bone recovery, so most patients should expect a longer course (30 to 60 sessions) and more gradual symptom improvement than in mandibular ORN. Most patients tolerate the course well; common side effects are temporary near-sightedness during treatment, ear barotrauma (managed with pressure-equalisation), and mild fatigue.
Chondroradionecrosis is publicly funded as a Health Canada-recognised indication (categorised under UHMS condition #11 Delayed Radiation Injury, sub-category radiation damage affecting bone) at all 11 hospital hyperbaric programmes in Canada. Coverage applies under OHIP, MSP, AHCIP, RAMQ, MSI, MCP, and Saskatchewan Health.
In Ontario, OHIP covers treatment at the three hospital programmes (Toronto General / UHN, Hamilton General Hospital, The Ottawa Hospital). Toronto General has particularly close working relationships with the major head-and-neck cancer centres including the Princess Margaret Cancer Centre, Sunnybrook Health Sciences, and Mount Sinai Hospital. In British Columbia, treatment is at Vancouver General Hospital, with referrals from the BC Cancer Agency head-and-neck programme. In Alberta, both Misericordia Edmonton (Covenant Health) and the Foothills Medical Centre / AJECCC Calgary (Alberta Health Services) accept chondroradionecrosis referrals from the Cross Cancer Institute and the Tom Baker Cancer Centre respectively, with the Alberta hospital billing code 13.99I (per 15 minutes). RAMQ covers treatment at Hôpital du Sacré-Cœur de Montréal and Hôtel-Dieu de Lévis in Quebec. MSI (Nova Scotia), MCP (Newfoundland and Labrador), and Saskatchewan also cover their respective hospital programmes.
For laryngeal chondroradionecrosis with airway compromise, urgent inter-facility transfer through CritiCall Ontario at 1-800-668-4357 or the equivalent provincial transfer service is appropriate. Routine non-urgent referrals follow standard cancer-care pathways through otolaryngology, head-and-neck surgery, or radiation oncology. Patients in provinces or territories without an in-province hospital hyperbaric programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, Nunavut) are referred interprovincially, with most cases routing to Misericordia Edmonton or the Ontario hospital programmes.
Hyperbaric oxygen therapy for the 14 Health Canada-recognised conditions, including Chondroradionecrosis, is delivered at the 11 hospital hyperbaric programmes located in seven provinces (Ontario, Quebec, British Columbia, Alberta, Nova Scotia, Newfoundland and Labrador, and Saskatchewan). The six provinces and territories without an in-province hospital programme (Manitoba, New Brunswick, Prince Edward Island, Yukon, Northwest Territories, and Nunavut) route patients to the nearest receiving hospital programme. Use the links below for province-specific coverage, referral pathway, and emergency routing details.
Hospital + Private
OHIP (Ontario Health Insurance Plan)
Hospital Only
MSP (Medical Services Plan)
Hospital + Private
Alberta Health / AHCIP
Hospital Only
RAMQ
Disrupted
Saskatchewan Health Authority
No Hospital Chamber
Manitoba Health
Hospital Only
MSI (Medical Services Insurance)
No Hospital Chamber
Medicare NB
Hospital Only
MCP (Medical Care Plan)
Out-of-Province Referral
Health PEI
Out-of-Province Referral
Yukon Health and Social Services
Out-of-Province Referral
NWT Health and Social Services
Out-of-Province Referral
Nunavut Department of Health
For acute or emergency presentations of Chondroradionecrosis, call 911 first. The receiving emergency department coordinates urgent transfer to the nearest hospital hyperbaric programme through the relevant provincial transfer network (CritiCall Ontario at 1-800-668-4357, BC Patient Transfer Network, EHS Nova Scotia, or equivalent). For diving-related emergencies, the Divers Alert Network (DAN) emergency hotline is 1-919-684-9111.
Absolute contraindications to HBOT include untreated pneumothorax (because trapped intrathoracic air expands on decompression and can cause tension pneumothorax), concurrent bleomycin chemotherapy (because hyperbaric oxygen can trigger or accelerate oxygen-induced pulmonary fibrosis), and concurrent disulfiram (because it inhibits superoxide dismutase, the enzyme that neutralises hyperbaric-oxygen-generated free radicals). Prior bleomycin exposure with documented pulmonary clearance is a relative contraindication that requires individualised pulmonary-function review before HBOT. Relative contraindications include severe chronic obstructive pulmonary disease with bullous lung disease, uncontrolled seizure disorder, claustrophobia, recent middle-ear or sinus surgery (relevant for head-and-neck radiation patients with prior surgical history), and uncontrolled hypertension. For laryngeal cases with significant airway compromise, the treating ENT team manages airway stabilisation before initiating HBOT; HBOT does not relieve acute airway obstruction and should not delay airway intervention when needed. Active tumour recurrence in the planned treatment field is a relative contraindication, and biopsy with multidisciplinary tumour-board review is standard pre-treatment work-up to confirm absence of recurrence.
A delayed complication of radiotherapy in which previously irradiated cartilage and adjacent bone undergo progressive necrosis months to years after treatment. It most commonly affects the laryngeal cartilage in patients treated for laryngeal or hypopharyngeal cancer (laryngeal chondroradionecrosis) but can also affect costal cartilage following thoracic radiotherapy and other irradiated cartilaginous structures. It is clinically distinct from the much more common mandibular osteoradionecrosis (ORN) and is often misdiagnosed.
Yes. Chondroradionecrosis is treated as part of "radiation damage affecting bone" on Health Canada's 14 recognised conditions list (UHMS condition #11 Delayed Radiation Injury). HBOT is publicly funded at all 11 hospital hyperbaric programmes across Canada under OHIP, MSP, AHCIP, RAMQ, MSI, MCP, and Saskatchewan Health, with a physician referral from otolaryngology, head and neck surgery, radiation oncology, or thoracic surgery.
Distinguishing the two is one of the most challenging diagnostic problems in post-radiation head-and-neck care. Imaging features (CT, MRI, PET-CT) and endoscopic appearance can substantially overlap. Definitive distinction typically requires biopsy with multidisciplinary tumour-board review by a head-and-neck cancer team. The decision to start HBOT typically follows confirmation that the diagnosis is necrosis, not active disease, because HBOT is contraindicated in active recurrent malignancy in the planned treatment field.
Standard course is 30 to 40 daily sessions at 2.0 to 2.4 ATA on 100 percent oxygen for 90 minutes per session, delivered five days per week. Extension to 60 sessions is common in severe cases or when response is partial but continuing. The Marx-style 30-and-10 protocol applies when surgical resection or reconstruction is planned (30 sessions before surgery, 10 after).
HBOT addresses the underlying tissue ischaemia and supports healing, but acute airway compromise requires immediate ENT management for airway stabilisation. HBOT does not relieve acute airway obstruction and is typically initiated after the airway is secured, in coordination with the treating ENT team. For severe cases with imminent airway compromise, urgent inter-facility transfer through CritiCall Ontario at 1-800-668-4357 or the equivalent provincial transfer service may be appropriate.
Cartilage is largely avascular and cannot directly revascularise the way bone can. Chondrocytes derive their oxygen and nutrients by diffusion from the perichondrium and adjacent vascular tissue. HBOT works on cartilage primarily by improving the perichondrial blood supply and the oxygenation of the surrounding bony and soft-tissue envelope. Response is generally slower than in pure osteoradionecrosis, long-standing severe cartilage destruction has limited recoverability, and surgical reconstruction (with HBOT support before and after) is more often required for definitive management than in the typical mandibular ORN case.
Speak with your otolaryngologist, head-and-neck surgical oncologist, radiation oncologist, or (for thoracic cases) thoracic surgeon. They will arrange biopsy with multidisciplinary tumour-board review to confirm the diagnosis and exclude cancer recurrence, then refer you to the nearest hospital hyperbaric programme. Earlier referral after symptom onset, before extensive cartilage destruction develops, is associated with better outcomes.
All 11 Canadian hospital hyperbaric programmes accept chondroradionecrosis referrals. The Canada Hyperbarics verified directory at canadahyperbarics.ca/facilities/ lists all programmes with phone numbers, addresses, and current operational status. Toronto General Hospital (UHN), Hamilton General Hospital, The Ottawa Hospital, Vancouver General Hospital, Misericordia Edmonton, and Foothills/AJECCC Calgary have the strongest integration with major head-and-neck cancer centres.
Related conditions: Delayed Radiation Injury and HBOT
Latest Articles
TL;DR: Osteoradionecrosis (ORN) of the jaw is a late complication of head and neck radiotherapy. Hyperbaric oxygen therapy…
TL;DR: Radiation damage after head and neck cancer is a set of late complications that can develop months…
TL;DR: Osteoradionecrosis (ORN) is one of the most serious complications of radiation therapy for head and neck cancer.…